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The unfolded protein response (UPR) is a stress response that is activated upon disturbed homeostasis in
the endoplasmic reticulum. In Alzheimer’s disease, as well as in other tauopathies, the UPR is activated in
neurons that contain early tau pathology. A recent genome-wide association study identiﬁed genetic
variation in a UPR transducer as a risk factor for tauopathy, supporting a functional connection between
UPR activation and tau pathology. Here we show that UPR activation increases the activity of the major
tau kinase glycogen synthase kinase (GSK)-3 in vitro via a selective removal of inactive GSK-3 phos-
phorylated at Ser21/9. We demonstrate that this is mediated by the autophagy/lysosomal pathway. In
brain tissue from patients with different tauopathies, lysosomal accumulations of pSer21/9 GSK-3 are
found in neurons with markers for UPR activation. Our data indicate that UPR activation increases the
activity of GSK-3 by a novel mechanism, the lysosomal degradation of the inactive pSer21/9 GSK-3. This
may provide a functional explanation for the close association between UPR activation and early tau
pathology in neurodegenerative diseases.
 2013 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Aggregates of the microtubule associated protein tau are found
in several neurodegenerative disorders, commonly referred to as
tauopathies. This includes Alzheimer’s disease (AD), Pick’s disease
(PiD), progressive supranuclear palsy (PSP), and frontotemporal
dementia and parkinsonism linked to chromosome 17 (FTDP-17)
(Ballatore et al., 2007; Gendron and Petrucelli, 2009), a familial
tauopathy that is associated with mutations in the gene encoding
tau. Tau is predominantly involved in facilitating the structure
and function of microtubules. Under physiological conditions,
tau phosphorylation is a rapid and reversible process, mediated
by the opposing actions of several protein kinases and phospha-
tases (Cowan et al., 2010; Cuchillo-Ibanez et al., 2008). In contrast,
hyperphosphorylation of tau is thought to precede the format-
ion of tau aggregates and is therefore associated with pathologyAnalysis, Academic Medical
Netherlands. Tel.: þ31-20-
r).
.
evier OA license.(Alonso et al., 2001; Alonso et al., 2010; Bancher et al., 1989; Rankin
et al., 2008).
The unfolded protein response (UPR), a stress response pathway
that is activated upon a disturbance in endoplasmic reticulum (ER)
homeostasis, is strongly associated with the pathology of tauo-
pathies (Hoozemans et al., 2009; Nijholt et al., 2011c). Three ER
transmembrane proteins function as stress sensors andmediate the
effects of the UPR: PERK, IRE1, and ATF6. During ER stress, these
proteins are activated by phosphorylation (PERK and IRE1) or
cleavage (ATF6), and activate responses aimed at restoring homeo-
stasis in the ER (Schroder and Kaufman, 2005). Activation of the UPR
leads to the following: an overall reduction in translation to reduce
the amount of novel polypeptides in the ER, and the transcriptional
and translational upregulation of factors that facilitate protein
folding and degradation. We and others previously reported UPR
activation markers in close spatio-temporal connection with phos-
phorylated tau in AD brain (Hoozemans et al., 2005; Hoozemans
et al., 2009; Unterberger et al., 2006). Our group observed the
same association of the UPR and phosphorylated tau protein in non-
AD tauopathies, including cases of sporadic PiD, PSP, and FTDP-17
(Nijholt et al., 2011c). In this cohort, the involvement of amyloid
b (Ab) pathology and overall ageing effects could be excluded,
D.A.T. Nijholt et al. / Neurobiology of Aging 34 (2013) 1759e17711760strengthening the connection between the UPR and early tau
pathology. Interestingly, a recent genome-wide association study
has identiﬁed genetic variation in the gene encoding the ER stress
transducer PERK as a risk factor for PSP, suggesting that perturbation
of the UPR can inﬂuence the risk for developing tau pathology
(Hoglinger et al., 2011).
A large number of kinases phosphorylate tau in vitro (Hanger
et al., 2009), but the precise mechanisms of physiological regula-
tion have not yet been elucidated. A major kinase implicated in
physiological and pathological phosphorylation of tau is glycogen
synthase kinase 3 (GSK-3). Tau is phosphorylated by GSK-3 in vitro
(Hanger et al., 1992; Ishiguro et al., 1992), in cultured cells
(Lovestone et al., 1994; Lovestone et al., 1996), and in transgenic
mice overexpressing GSK-3 (Brownlees et al., 1997; Gomez-Sintes
et al., 2007; Lucas et al., 2001). GSK-3 phosphorylates tau at
multiple sites, and most of these sites are also phosphorylated in
disease (Hanger et al., 1992; Hanger and Noble, 2011; Wagner et al.,
1996). GSK-3 plays a role in a wide variety of signaling pathways
including glycogen metabolism, protein synthesis, mitosis,
apoptosis, andmicrotubule dynamics (Forde and Dale, 2007). GSK-3
exists as 2 highly homologous isoforms, GSK-3a and GSK-3b, which
are encoded by different genes located on chromosomes 19 and 3,
respectively (Woodgett, 1990). Both isoforms are expressed in the
brain (Lau et al., 1999; Yao et al., 2002), however GSK-3b appears to
be the predominantly expressed isoform (Lau et al., 1999). Some,
but not all, substrates require priming by phosphorylation at
a nearby residue by another kinase that enables phosphorylation by
GSK-3 (Bax et al., 2001; Fiol et al., 1987). GSK-3b phosphorylates tau
at primed and unprimed sites; however, phosphorylation at primed
sites was shown to play a key role in regulating in vitro tau
microtubule binding (Cho and Johnson, 2003). GSK-3 activity is
inhibited by phosphorylation of the Ser21 and Ser9 residue in GSK-
3a/b, respectively. This residue is located in the N-terminus of GSK-
3; when phosphorylated, this acts as a primed pseudo-substrate
that loops back in the active site (Forde and Dale, 2007). Inhibi-
tory phosphorylation of GSK-3 at this site occurs in response to
several signaling pathways. Protein kinase A phosphorylates GSK-3
upon an increase in levels of the second messenger cyclic AMP,
caused by binding of ligands to G-proteinecoupled receptors on the
cell membrane (Fang et al., 2000). The insulin signaling pathway
leads to increased activity of phosphatidyl inositol kinase 3 (PI3K)
and protein kinase B (PKB)/Akt. The commonly used activator of
GSK-3, wortmannin (Wm), inhibits PI3K and in this manner
prevents inhibitory phosphorylation by PKB/Akt (Grimes and Jope,
2001; Li et al., 2006). Phosphorylation of GSK-3a/b at Tyr216 and
Tyr279, respectively, is associated with increased GSK-3 activity (Bax
et al., 2001). Inhibition of this phosphorylation event either by
enzymatic dephosphorylation or mutation of Tyr into Phe,
decreases the kinase activity (Hagen et al., 2002). Phosphorylation
at the Tyr residue is suggested to be an autophosphorylation event;
however, some kinases have been shown to target GSK-3 Tyr216/279
in vitro (Hartigan et al., 2001; Lesort et al., 1999; Medina and
Wandosell, 2011). The precise mechanism remains unknown but
the position of the Tyr216/279 residue in the GSK-3 activation loop
suggests it induces a conformational change that results in more
efﬁcient substrate binding (Bax et al., 2001; Hagen et al., 2002).
The role of GSK-3 in tau pathology has been the subject of
several studies; however, its regulation and involvement in the
pathogenesis of tauopathies is not yet fully elucidated. GSK-3b co-
isolates with brain-derived microtubules (Ishiguro et al., 1993)
and, in cells, phosphorylates tau at epitopes also found in AD
(Hanger et al., 1992; Lovestone et al., 1994). Inhibition by lithium or
more speciﬁc GSK-3 inhibitors have prevented tau phosphorylation
and aggregation in several murine models (Leroy et al., 2010; Noble
et al., 2005; Sereno et al., 2009). The association of the UPR withearly tau pathology prompted the investigation of effects of in vitro
UPR induction on GSK-3 activity. Chemical induction of the UPR
results in decreased phosphorylation at the inhibitory Ser21/9
epitope and increased phosphorylation at the activating Tyr279/216
epitope (Fu et al., 2010). Another study identiﬁed only decreased
Ser21/9 phosphorylation (Song et al., 2002). Although the mecha-
nism remains elusive, these studies suggest that activation of the
UPR leads to increased activity of GSK-3.
In this study, we further investigated the connection between
activation of the UPR and GSK-3 activity in vitro. Furthermore, we
analyzed the presence of GSK-3 in connection to UPR activation and
tau pathology in post-mortem brain material from patients with
different types of tauopathies. Our data provide evidence for UPR-
induced regulation of GSK-3 activity via lysosomal degradation.
2. Methods
2.1. Cell culture, differentiation, and treatment
Human SK-N-SH neuroblastoma cells were cultured in Dulbec-
co’s modiﬁed Eagle’s mediumwith GlutaMax (Gibco BRL, Carlsbad,
CA) supplemented with 10% fetal calf serum (Lonza, Basel,
Switzerland) and 100 U/mL penicillin (Yamanouchi Pharma BV,
Leiderdorp, the Netherlands). Cells were differentiated in culture
medium supplemented with all trans-retinoic acid (Sigma, St Louis,
MO) in a ﬁnal concentration of 10 mmol/L for 5 days. Differentiated
cells were subsequently treated with tunicamycin (Tm), lithium
chloride (LiCl), and Baﬁlomycin (BAF) at indicated concentrations
for 16 hours. Treatment with wortmannin (Wm) was performed at
100 nmol/L for 1 hour before harvest. For starvation, medium was
removed and cells were washed twice in phosphate-buffered saline
(PBS) to remove excess nutrients. Cells were subsequently cultured
for 2 hours in Earle’s balanced salt solution (Sigma), which lacks
essential amino acids.
Dissociated cortical neurons were prepared from embryonic day
18 mice as described elsewhere (De Wit et al., 2009). Cerebral
cortices were dissected in Hanks Buffered Salts Solution (HBSS,
Sigma) anddigestedwith 0.25% trypsin (Invitrogen Life Technologies,
Carlsbad, CA, USA) for 20 minutes at 37 C. Tissue was washed and
triturated with ﬁre-polished Pasteur pipettes, counted, and plated in
6-well plates (200,000 neurons per well) in Neurobasal medium
supplemented with 2% B-27, 1.8% HEPES, 1% glutamax, and 1% Pen-
Strep (all from Invitrogen). For immunocytochemistry, high-density
cultures (25,000 neurons per well) were plated on pre-grown
cultures of rat glia cells (37,500 cells per well) on 18-mm glass
coverslips in 12-well plates. Neurons were treated with Tm at DIV7.
2.2. ELISA colorimetric assay
The InCell ELISA colorimetric assay (Thermo Scientiﬁc,Waltham,
MA) was performed according to the manufacturer’s recommen-
dations. In short, SK-N-SH cells were plated in 96-well plates
(15,000 cells per well) and differentiated as described above. All
conditions were assayed in triplicate. Unless otherwise stated, all
incubations were performed at room temperature (RT) with gentle
rocking. Cells were ﬁxed in 4% formaldehyde for 15 minutes.
Formaldehyde was aspirated; cells were washed twice in 1x Tris
buffered saline (TBS) and incubated with permeabilization buffer
for 15 min. After permeabilization, cells were washed with 1x TBS
and incubated with quenching solution (containing H2O2) for 20
minutes. Cells were washed with 1x TBS and subsequently blocked
for 30 minutes in blocking solution. After blocking, cells were
incubated with the primary antibody solution for 16 hours at 4 C.
Antibodies and their dilutions are described in Table 1. Cells were
washed 3 times with wash buffer and subsequently incubated with
Table 1
Primary antibodies used in this study
Antibody Species Dilutions Source
IHC single/double InCell ELISA Western blot IF
pPERK Rabbit /1:800 e e e Santa Cruz Biotechnology, Santa Cruz, CA
AT8 Mouse 1:1000/1:100 e e e Pierce, Rockford, IL
GSK-3 Rabbit 1:500/1:50 1:200 1:1000 1:100 Cell Signalling Technology, Danvers, MA
pSer21/9 GSK-3 Rabbit 1:100/1:10 1:100 e e Cell Signalling Technology
pTyr216/279 GSK-3 Mouse 1:100 e e e Millipore, Billerica, MA
BiP Goat e 1:100 e e Santa Cruz Biotechnology
Cathepsin D Mouse /1:1000 e e e Millipore
LAMP1 Mouse e e e 1:100 Santa Cruz Biotechnology
LAMP1 Rat e e e 1:200 Biolegend, San Diego, CA
eEF2a Rabbit e e 1:1000 e Cell Signalling
GAPDH Mouse e e 1:1000 e Millipore
Key: ELISA, enzyme-linked immunosorbent assay; IF, immunoﬂuorescence; IHC, immunohistochemistry.
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goat for BiP antibody) for 30minutes. Cells werewashed, and signal
was developed by addition of 3,30,5,50-tetramethylbenzidine (TMB)
substrate. The reaction was stopped when blue color was visible.
Absorbance (A) was measured at 450 nm using a FLUOstar Omega
microplate reader (BMG Labtech GmbH, Ortenberg, Germany). To
correct for variation in the amount of cells, Janus Green whole cell
stain was used. Cells were incubated with Janus Green whole cell
stain for 5 minutes and subsequently washed with ultrapure water
until all excess stain was removed. Elution buffer was added and
cells were incubated for 10 minutes before absorption was
measured at 615 nm. The A 450-nm values were normalized to A
615-nm values. The normalized A 450-nm values were used to
calculate fold changes in assayed protein levels.
2.3. Western bloting
SK-N-SH cells were harvested by scraping in 1% (v/v) Triton/PBS
lysis buffer and neurons by scraping in RIPA lysis buffer (50 mmol/L
Tris pH 7.6, 150 mmol/L NaCl, 1% NP-40, 0,5% sodium deoxycholate,
0,1% SDS, 2 mmol/L EDTA) supplemented with Complete protease
inhibitors and PhosSTOP (Roche Diagnostics, Mannheim, Germany).
Cell lysates were incubated for at least 15 minutes at 4 C and
centrifuged at 20.000 g for 20 minutes at 4 C. Supernatant
protein concentration was determined by Bio-Rad Protein Assay
(Bio-Rad, Hercules, CA) or BCA (Thermo Scientiﬁc, Rockford, IL).
Equal amounts of proteinwere loaded in each lane on a 10% SDS gel.
Proteins were blotted onto nitrocellulose membrane using a semi-
dry blotting apparatus. Membrane was washed with TBST (0.05%
Tween-20 in TBS), blocked with 5% Bovine serum albumin (BSA) in
TBS-T (blocking solution) for 1 hour and subsequently incubated
with the primary antibody in blocking solution overnight. After
washing with TBS-T, membrane was incubated with species-
speciﬁc secondary antibodies conjugated to horseradish peroxi-
dase (dilution 1:2000, Dako, Glostrup, Denmark) for 1 hour.
Membrane was washed and protein signals were visualized using
LumiLightPLUS Western blotting substrate (Roche Diagnostics,
Mannheim, Germany) and a LAS-3000 luminescent image analyzer
(Fuji Photo Film [Europe], Kleve, Germany). Results were analyzed
using Advanced Image Data Analyzer software (Raytest, Strau-
benhardt, Germany) version 3.44.035.
2.4. GSK-3 activity assay
GSK-3 activity was measured in crude cell extracts of differen-
tiated SK-N-SH cells using an assay described previously (Ryves
et al., 1998). Differentiated SK-N-SH cells were washed once in ice-
cold PBS and scraped in ice-cold lysis buffer (50 mmol/L Tris-HCL,pH 8.0, 150 mmol/L NaCl, 5 mmol/L ethylenediaminetetraacetic
acid (EDTA), 50 mmol/L NaF, 10 mmol/L DTT, and 1% Triton X-100)
supplemented with PhosSTOP phosphatase inhibitor (Roche, Basel,
Switzerland) and Protease Inhibitor Cocktail (Roche). Lysates were
cleared by centrifugation at 14,000 g for 10 minutes. A Bradford
protein assay (BioRad, Hercules, CA) was used to determine the
protein concentration in each sample.
For each assay, 12.5 mL of cell extract was incubated with 10 mg
GSK-3 substrate peptide (Phospho-GS-peptide-2, Upstate Biotech-
nology, Lake Placid, NY) and 6.25 mL ATP hot mix (200 mmol/L
HEPES, pH 7.5, 50 mmol/L MgCl2, 8 mmol/L DTT, 400 mmol/L ATP,
and 1 mCi/ mL [g32P] ATP (10mCi/mL; Perkin-Elmer, Waltham, MA)).
All samples were assayed in the presence and absence of 20mmol/L
LiCl. The substrate peptide used is based on glycogen synthase,
a known GSK-3 substrate. The sequence was as follows:
YRAAVPPSPSLSRHSSPHQpSEDEEE, with p representing the site of the
primed phosphate that is necessary for phosphorylation by GSK-3.
Assays were incubated at RT and terminated after 8 minutes by
spotting onto p81 ion-exchange paper (Whatman GmbH, Dassel,
Germany). The membrane was washed 3 times in a large volume of
100 mmol/L phosphoric acid, and bound radioactivity was quanti-
ﬁed by scintillation counting. Measured values were corrected for
protein content.2.5. Single immunohistochemistry
Post-mortem brain material was obtained from the Netherlands
Brain Bank (Table 2). Informed consent was obtained for each
patient. Sections (5 mm thick) were mounted onto Superfrost plus
tissue slides (Menzel-Gläser, Braunschweig, Germany) and dried
overnight at 37 C. For all stainings, sections were deparafﬁnized
and immersed in 0.3% H2O2 in methanol for 30 minutes to quench
endogenous peroxidise activity. Sections were washed 5 minutes
in PBS and treated with 10 mmol/L, pH 6.0, sodium citrate buffer
heated by microwave for 10 minutes for antigen retrieval. Sections
were subsequently incubated with primary antibody (Table 1)
for 16 hours at 4 C. All primary and secondary antibodies were
diluted in PBS containing 1% (w/v) Bovine serum albumin (BSA;
Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany).
Negative controls were created by primary antibody omission.
Sections were washed 3 times for 10 minutes with PBS and
subsequently incubated with horseradish peroxidiseelabeled a-
mouse/rabbit secondary antibody (Dako REAL EnVision/HRPRabbit/
Mouse, Dako). Color was developed using 3,3-diaminobenzidine
(DAB; 0.1 mg/ml, 0.02% H2O2, 10 minutes; Sigma, St. Louis, MO)
as chromogen. Sections were counterstained with hematoxylin
and mounted using Depex (BDH laboratories Supplies, East
Grinstead, UK).
Table 2
Cases used for immunohistochemical analysis
Case
patient
Clinical
diagnosis
MAPT
mutation
Age
(y)
Sex Cause of
death
PMD
(hrs:min)
1 PiD e 68 F Pneumonia 6:46
2 PiD e 57 M General deterioration 6:40
3 PiD e 70 M Pneumonia 5:15
4 PiD e 82 M Pneumonia 4:10
5 PSP e 75 M Unknown 5:05
6 PSP e 72 F Infection 6:15
7 PSP e 80 M Dehydration, uremia 4:50
8 PSP e 67 M Pneumonia 6:45
9 PiD G272V 54 F Cachexia and dehydration 5:40
10 PiD G272V 54 F Cardiac arrest 7:30
11 PiD G272V 67 F Cachexia and dehydration 4:10
12 FTD G272V 49 M Suffocation (unnatural death) 5:10
13 FTD G272V 51 M Pneumonia 4:25
14 PiD P301L 64 F Unknown 5:10
15 PiD P301L 66 F Cachexia and dehydration 6:40
16 PiD P301L 46 M Unknown 5:35
17 PiD P301L 66 M Pneumonia 5:00
18 CTRL e 66 M Abdominal aortic aneurysm 7:45
19 CTRL e 61 F Euthanasia 6:50
Key: CTRL, control; F, female; FTD, frontotemporal dementia; GFM, gyrus frontalis
medialis; HIP, hippocampus; M, male; MAPT, microtubule associated protein tau;
PiD, Pick’s disease; PMD, post mortem delay; PSP, progressive supranuclear palsy.
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2.6.1. pPERK and GSK-3/pSer21/9 GSK-3
After quenching endogenous peroxidase activity, sections were
pre-incubated with normal swine serum (1:10 dilution) for 10
minutes and subsequently incubated with pPERK antibody for
60 minutes at RT. After washing, sections were incubated with
biotin-conjugated swine anti-rabbit F(ab’)2 (1:300 dilution) for 30
minutes at RT, washed and incubated with alkaline phosphatase-
conjugated streptavidin (sAP, 1:100 dilution). Color was devel-
oped using Liquid Permanent Red (LPR; Dako) as chromogen.
Sections were treated in 10 mmol/L, pH 6.0, sodium citrate buffer
heated by autoclave for 10 minutes and incubated for 16 hours at
4 C with mouse anti-GSK-3 or rabbit anti-pSer21/9 GSK-3. After
washing, sections were incubated with EnVision goat anti-mouse
HRP or goat anti-rabbit HRP (undiluted, Dako) for 30 minutes at
RT. Color was developed using DAB as chromogen.
2.6.2. AT8 and GSK-3/pSer21/9 GSK-3
Sections were preincubated with NGS (1:10 dilution) for 10
minutes, incubated with AT8 antibody for 60 minutes at RT, and
after washing incubated with EnVision goat anti mouse HRP
(undiluted; Dako) for 30 minutes at RT. Color was developed using
DAB. After washing and treatment in 10 mmol/L sodium citrate
buffer pH, 6.0, in the autoclave for 10 minutes, sections were pre-
incubated with NGS (1:10 dilution) for 10 minutes and subse-
quently incubated with GSK-3 antibody for 16 hours at 4 C. After
washing, sections were incubated with sAP (1:100 dilution) for 60
minutes at RT, and color was developed using LPR.
For AT8 and pSer21/9 GSK-3 double immunohistochemistry
sections were treated as described above and subsequently incu-
bated with a mix of AT8 and pSer21/9 GSK-3 for 16 hours at 4 C.
Sections were washed in PBS and subsequently incubated with
a mix of SwaRBIO (1:300 dilution) and GaMIgG1HRP (1:100 dilution)
for 60 minutes at RT. Sections were washed and incubated with sAP
(1:100 dilution) for 60 minutes at RT. Sections were developed
using DAB, and subsequently using LPR.
2.6.3. Cathepsin D and pSer21/9 GSK-3
Endogenous peroxidise activity was quenched and sectionswere
treated in 10 mmol/L sodium citrate buffer, pH6.0, in a microwavefor 10minutes. Sectionswere preincubatedwithNGS (1:10 dilution)
for 10 minutes at RT and subsequently incubated with a mix of
cathepsin D and pSer21/9 GSK-3 for 16 hours at 4 C. After washing,
sectionswere incubatedwith SwaRBIO (1:300 dilution) and Envision
goat anti mouse HRP (undiluted, Dako) for 60 minutes at RT.
Sections were washed and incubated with sAP (1:100 dilution) for
60 minutes at RT. Sections were developed using DAB, and subse-
quently developed using LPR.
For all double stainings, nuclei were stained with hematoxylin,
and sections were mounted using Aquamount (BDH Laboratories
Supplies, Radnor, PA). Cross-reactivity controls were generated by
omission of primary antibodies. The Nuance spectral imaging
system (Cri; Woburn, MA) was used to analyze the double-stained
sections (Nijholt et al., 2011c). Spectral libraries of single-brown
(DAB), single-red (LPR), and hematoxylin were obtained from
control sections. The spectral library was used to unmix the
different reaction products in double-stained sections into black
and white images. These images represent the localization of each
reaction product, and were converted to ﬂuorescent-like images
composed of pseudo-colors by the Nuance software.
2.7. Immunocytochemistry
Paraformaldehyde (PFA), 4% in PBS, was added to the medium in
the well for 5 minutes at RT to obtain a 2% PFA solution for pre-
ﬁxation. Subsequently, cells were ﬁxed with 4% PFA in PBS for
10 minutes. All washing steps were performed with PBS and
repeated 3 times. Antibodieswere diluted in 5% (w/v) BSA fraction V
(RocheDiagnostics,Mannheim,Germany) in PBS. Cellswerewashed
and blocked for 30 minutes at RT with 5% BSA in PBS containing
0.5% (v/v) Triton for cell permeabilization and incubated with the
LAMP1 antibody for 2 h at RT. After washing, anti-rat secondary
antibody (Jackson ImmunoResearch, West Grove, PA) was applied
for 1 hour at RT. Cells were washed and incubated with GSK-3
antibody overnight at 4 C. Washing was followed by incubation of
the anti-rabbit secondary antibody (Jackson ImmunoResearch) in
a dark chamber for 1 hour. Cellswerewashedbefore incubationwith
40,6-diamidino-2-phenylindole (DAPI) for 5 minutes. After a ﬁnal
washing step, cells were mounted with Prolong Gold Antifade
Reagent (Invitrogen).
3. Results
3.1. UPR activation decreases total and pSer21/9 GSK3 levels and
increases GSK-3 activity in vitro
We investigated the effect of UPR activation on the phosphor-
ylation status of GSK-3 in vitro. An InCell ELISA colorimetric assay,
combined with GSK-3 and phosphorylated GSK-3 speciﬁc anti-
bodies, was used to investigate GSK-3 in differentiated SK-N-SH
neuroblastoma cells. The different (phospho) speciﬁc antibodies
used in this study do not distinguish the paralogous proteins
GSK-3a and GSK-3b. Cells were treated with tunicamycin (Tm) to
chemically induce the UPR. Tm inhibits N-linked glycosylation,
leading to the accumulation of proteins in the ER and subsequent
activation of the UPR. Wm and lithium chloride (LiCl) were used as
controls for stimulation and inhibition of GSK-3 activity, respec-
tively. When pSer21/9 and pTyr216/279 GSK-3 are presented as
a percentage of total GSK-3, Tm led to a decrease in pSer21/9 (13%,
22%, and 16% reduction, p < .01) and an increase in pTyr216/279
GSK (18%, 15% (p < .01) and 27% increase (p < .05), for 0.2, 0.5, and
1.0 mg/mL Tm, respectively), ﬁndings that are indicative of increased
GSK-3 activity (Fig. 1A). In accordance with the literature, Wm
resulted in 50% (p < .01) decrease (Grimes and Jope, 2001; Li et al.,
2006) and LiCl in 15% (p < .05) increase (Chalecka-Franaszek and
Fig. 1. UPR activation reduces pSer21/9 GSK-3 levels and increases GSK-3 activity. Differentiated SK-N-SH cells were treated with increasing concentrations of Tm for 16h. Treatment
with Wm and LiCl are indicated as positive and negative controls. Total and phosphorylated levels of GSK-3 and the ER chaperone BiP were investigated using an InCell ELISA
colorimetric assay. One representative experiment for the InCell ELISA assay is shown; all measurements were performed in triplicate and each experiment was performed at least 3
times. (A) pSer21/9 and pTyr216/279 are expressed as a percentage of total GSK-3. Untreated cells are set to 100%. (B) Levels of BiP increased after treatment with Tm, indicating that the
UPR is active under these conditions. (C) Differentiated SK-N-SH cells were incubated for 16 hours with (Tm) or without (crtl) 1 mg/mL Tm and (D) mouse primary neurons were
treated for 16 hours with or without 5 mg/mL Tm. Equal amounts of cell extracts were analysed by Western blotting using antibodies as stated, eEF2a, and GAPDH were used as
loading control. (E) Total GSK-3, pSer21/9 GSK-3, and pTyr216/279 GSK-3 levels corrected for the amount of cells by Janus Green staining. Values in untreated cells are set to 100%. (F)
GSK-3 activity was determined by measuring the incorporation of radioactive phosphate on a GSK-3 speciﬁc substrate peptide in lysates of SK-N-SH cells treated with Tm and Wm.
Bars represent the mean  SEM of 2 independent experiments. *p < .05, **p < .01.
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inhibition of GSK-3 activity, respectively (Fig. 1A). BothWm and LiCl
did not affect pTyr216/279 GSK-3 levels. Levels of the UPR target BiP
increased after Tm treatment (29%, 52%, and 81% increase (p < .05)
for 0.2, 0.5, and 1.0 mg/mL Tm, respectively), indicating that the UPR
is also activated in a dose-dependent manner under these condi-
tions (Fig. 1B). At a concentration of 0.1 mg/mL Tm, we found no UPR
activation (not shown), therefore the lowest concentration used in
our experiments was 0.2 mg/mL. As expected, neither Wm nor LiCl
led to increased BiP levels.
The observed changes can be caused by a direct effect on
phosphorylation or a change in GSK-3 levels. Therefore, the total
GSK-3 level was determined after Tm treatment on Western blot
and showed a decrease in the total levels (Fig. 1C). This Tm-induced
decrease in total levels of GSK-3 is also found in mouse primaryneurons (Fig.1D), indicating that this is notmerely a speciﬁc feature
of neuroblastoma cells (a higher Tm concentration was used in the
primary neurons to elicit a comparable UPR response, data not
shown). To investigate whether the GSK-3 phosphoforms are
differentially affected by Tm treatment, the data from the InCell
ELISA were represented relative to the number of cells. Tm treat-
ment led to a decrease in pSer21/9 GSK-3 levels (20% (p < .05), 33%,
and 36% (p < 0.01) reduction for 0.2, 0.5, and 1.0 mg/mL Tm,
respectively), whereas pTyr216/279 GSK-3 levels did not change
(Fig. 1E). Interestingly, treatment with Tm also caused a dose-
dependent decrease in total GSK-3 levels that reached statistical
signiﬁcance for 0.5 mg/mLTm (14% reduction, p< .05) and 1.0 mg/mL
Tm (23% reduction (p < .01). This is corroborated by quantiﬁcation
of total GSK-3 corrected for eEF2a after treatment with 1.0 mg/mL
Tm on Western blot (Fig. 1C; reduction 23%  0.10, n ¼ 4 from
D.A.T. Nijholt et al. / Neurobiology of Aging 34 (2013) 1759e17711764separate experiments). In summary, activation of the UPR with Tm
results in decreased levels of total and pSer21/9 GSK-3 in a dose-
dependent manner, where, at the highest concentration used,
both the UPR response and the effect at the total and pSer21/9 GSK-3
levels are most pronounced. Interestingly, we did not observe any
signiﬁcant changes in total GSK-3 levels after treatment with LiCl or
Wm, which are known to act on pSer21/9 phosphorylation itself,
suggesting that the UPR operates via a different mechanism.
Next we investigated whether the Tm-induced changes in the
relative amounts of pSer21/9 and pTyr216/279 GSK-3 have an actual
effect on protein kinase activity. The activity of GSK-3 was mea-
sured using an assay described by Ryves et al. (Ryves et al., 1998).
With this method, GSK-3 activity can be measured in crude cell
extracts. In short, the transfer of g-32P from [g-32P] ATP to a GSK-
3especiﬁc primed substrate peptide was measured using scintil-
lation counting. Each sample was assayed in the presence and
absence of LiCl, and the difference between these values was used
as a measure of GSK-3 activity. As expected, Wm resulted in an
increase in GSK-3 activity (80% increase; p < .05), indicating we can
measure changes in activity in this setup. Also Tm resulted in
a signiﬁcant and consistent increase in GSK-3 activity 21% increase,
(p < .05; Fig. 1F). These data are in accordance with the changes in
phosphorylation in GSK-3 after Tm treatment, and conﬁrm that UPR
activation leads to an increase in GSK-3 activity.
3.2. GSK-3 immunoreactive granules are present in hippocampal
neurons of tauopathy cases
Our in vitro data suggest a connection between UPR activation
and GSK-3 protein levels and protein kinase activity. We have
previously demonstrated that UPR activation occurs in AD and in
non-AD tauopathies in close relation to tau pathology (Hoozemans
et al., 2005; Hoozemans et al., 2009; Nijholt et al., 2011c). Therefore,
we investigated the expression of GSK-3 and its phosphorylation
status in the hippocampus of different tauopathies (Table 2). These
cases are clinically diagnosed with PiD, PSP, or FTD, and are histo-
pathologically classiﬁed as frontotemporal lobar degeneration with
tau positive inclusions (FTLD-tau). The hippocampi of these FTLD-
tau cases showed extensive tau pathology and UPR activation
(Nijholt et al., 2011c), making it a suitable region to investigate the
connection among UPR activation, tau phosphorylation, and GSK-3.
In all investigated cases, including non-demented controls, we
observed diffuse GSK-3 immunoreactivity in the soma and axons of
the hippocampal neurons. Little to no reactivity was evident in the
surrounding neuropil or in non-neuronal cells (Fig. 2A and B). In
addition, small but intensely stained GSK-3 immunoreactive gran-
ules were present in hippocampal neurons of all (both sporadic and
MAPT associated) tauopathy cases (Fig. 2C and D). We investigated
the phosphorylation status of GSK-3 using phospo-speciﬁc GSK-3
antibodies. ThepSer21/9 GSK-3 antibody showed little pSer21/9 GSK-3
immunoreactivity in the somaor axons of hippocampal neurons, but
revealed intensely stained immunoreactive granules in the tauop-
athy cases similar to those observed with the pan GSK-3 antibody
(Fig. 2EeG). Immunohistochemical staining for pTyr216/279 GSK-3
revealed a punctate staining pattern, and we observed no differ-
ences between control and tauopathy cases (data not shown).
Combined, our data show that granules consisting of inactive, Ser21/9
phosphorylated, GSK-3 are present in the hippocampal neurons of
tauopathy cases and are not present in non-neurological controls.
3.3. GSK-3 immunoreactive granules occur in neurons that have
activated the UPR and early tau pathology
To more precisely investigate the connection between UPR
activation and GSK-3 immunoreactive granules, we performeddouble immunohistochemistry on a subset of our cohort (cases 2, 4,
10, and 15). Phosphorylated (p) PERK was used as a marker of an
active UPR and was combined with antibodies directed against
GSK-3 (Fig. 3AeC) and pSer21/9 GSK-3 (Fig. 3D and E). In all inves-
tigated cases, pPERK and GSK-3 or pSer21/9 GSK-3 immunoreactive
granules co-occurred in the same neurons. No direct colocalization
between pPERK and (pSer21/9) GSK-3 was observed. Quantiﬁcation
of the number of pPERK positive neurons that contain GSK-3
granules in a subset of patients showed a range of approximately
20% to 60% per microscopic ﬁeld with an average of 34% to 45% for
the whole hippocampus (supplementary Table 1). We have previ-
ously demonstrated that UPR activation occurs in neurons in the
brain of AD (Hoozemans et al., 2009) and FTLD-tau (Nijholt et al.,
2011c) that contain phosphorylated tau that is not in densely
aggregated form. In Figure 4, we show that neurons with prebody
tau pathology contain (pSer21/9) GSK-3 immunoreactive granules
(Fig. 4AeD), whereas granules were not observed in neurons lack-
ing tau pathology (Fig. 4A, C, and E).
Thus, the ﬁndings that pSer21/9 GSK-3 granules accumulate in
neurons with an active UPR and phosphorylated tau suggests
a functional connection among UPR activation, GSK-3, and tau
phosphorylation.
3.4. pSer21/9 GSK-3 immunoreactive granules are positive for the
lysosomal protease cathepsin D
We have recently shown that UPR activation leads to the pref-
erential activation of the autophagy/lysosomal route to degrade
accumulated proteins (Nijholt et al., 2011c). Our in vitro data show
that levels of inactive pSer21/9 GSK-3 decrease after UPR activation,
whereas we ﬁnd accumulation of pSer21/9 GSK-3 in granules in UPR
positive neurons in tauopathies. This led us to hypothesize that,
during an active UPR, part of the GSK-3 pool is selectively degraded
by the lysosomal pathway.
To investigate whether UPR activation targets GSK-3 to the
lysosomal compartment, we studied the localization of GSK-3 in
differentiated SK-N-SH cells as well as in mouse primary neurons.
In both cell types, GSK-3 is abundant and diffusely distributed
throughout the cells (Fig. 5). Confocal analysis of double immuno-
ﬂuorescence staining with the lysosomalmembrane protein LAMP1
was performed. The LAMP1-positive structures are in the SK-N-SH
more conﬁned to a juxtanuclear site, whereas in the neurons they
are distributed throughout the soma. In both cell types, we observe
co-localization of GSK-3 with lysosomes, supporting a role for the
lysosomes in the degradation of GSK-3. However, in neither cell
type is relocalization of GSK-3 observed upon Tm treatment (Fig. 5).
This may be due to the high abundance of the GSK-3 throughout the
cells, which makes it technically difﬁcult to visualize a shift of a 20%
sub-pool with this technique.
To further investigate whether the GSK-3 positive structures in
tauopathies represents material targeted to lysosomes, we per-
formed double immunohistochemistry on cases 2 and 15, using
antibodies directed against the lysosomal protease cathepsin D and
pSer21/9 GSK-3. As expected, the cathepsin D antibody revealed
a granular staining pattern, in accordance with its presence in
lysosomes. A large fraction of pSer21/9 GSK-3-positive granules were
also cathepsin D positive (Fig. 6AeC). This indicates that, in tauo-
pathies, pSer21/9 GSK-3 is targeted to lysosomal structures in
neurons with an active UPR.
3.5. UPR induces lysosomal degradation of GSK-3 in vitro
If the lysosomal route is indeed responsible for UPR-mediated
degradation of GSK-3, then inhibition of lysosomal degradation
during the UPR should rescue GSK-3 levels in vitro. To investigate
Fig. 2. GSK-3 and pSer21/9 GSK-are localized in granules in hippocampal neurons in tauopathy cases. Immunohistochemistry was performed to evaluate the expression of GSK-3 and
its phosphorylation status in tauopathies. (A) Expression of GSK-3 is apparent in the pyramidal neurons of the hippocampus (control case). (BeG) Higher-magniﬁcation images are
shown from a representative control, sporadic PiD, and a MAPT mutation carrier assayed for the presence of total GSK-3 (BeD) and pSer21/9 GSK-3 (EeG). Intensely stained granules
were visible with the GSK-3 and pSer21/9 GSK-3 antibodies in tauopathy cases. Nuclei were counterstained using hematoxylin. Arrows indicate GSK-3 immunoreactive granules. Scale
bars, 200 and 50 mm.
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presence or absence of BAF. This compound inhibits lysosomal
degradation by inhibiting the vacuolar-type ATPase and increasing
the pH of lysosomal vesicles (Bowman et al., 1988; Drose et al.,
1993). Levels of GSK-3 were assayed using the InCell ELISA colori-
metric assay. As shown before, induction of the UPR led to
a signiﬁcant decrease in total GSK-3 levels. Co-treatment of Tmwith
BAF rescued the Tm induced degradation of GSK-3, whereas no
effect was observed on pTyr216/279 levels (Fig. 7A). This suggests that
a pTyr216/279 negative subset of GSK-3 is targeted for lysosomal
degradation during UPR activation. Based on our other data, we
suggest that pSer21/9 GSK-3 is a likely candidate for this selective
degradation by the lysosomes. We were unable to obtain infor-
mative results with pSer21/9 GSK-3, because treatment with BAF
alone decreased the level of pSer21/9 GSK-3 (Fig. 7A).
To verify that pSer21/9 GSK-3 is indeed a substrate for lysosomal
degradation, the activity of the autophagy/lysosomal pathway was
induced in SK-N-SH cells by amino acid deprivation (Mortimore
et al., 1989; Susan and Dunn, 2001) for 2 hours. Levels of GSK-3,
pSer21/9, and pTyr216/279 GSK-3 were assayed. Amino acid depriva-
tion led to a decrease in GSK-3 and pSer21/9 GSK-3 levels (Fig. 7B),
but had no effect on pTyr216/279 levels. This indicates that pSer21/9
but not pTyr216/279 GSK-3 is a substrate for autophagy and is
degraded in the lysosomes.4. Discussion
In this study, we have identiﬁed a speciﬁc mechanism for acti-
vation of GSK-3 via theUPR,whichmayexplain the close association
of the UPR and early stages of tau pathology. UPR activation in an
in vitro cell model led to a decrease in the levels of total and inactive
Ser21/9 phosphorylated GSK-3, resulting in a relative increase in
active Tyr216/279 phosphorylatedGSK-3 and increased protein kinase
activity. Increased activity of GSK-3 by UPR activation was previ-
ously observed (Fu et al., 2010; Song et al., 2002), but themechanism
has remained elusive. In the current study, we provide evidence that
UPR-mediated activation of the tau kinase GSK-3 occurs via the
lysosomal degradation of inactive GSK-3. This is compatiblewith the
pSer21/9GSK-3 functioning as a dominant negative, as has been
shown for catalytically inactive GSK-3 (Dominguez et al., 1995).
Regulation of total and pSer21/9GSK-3 by lysosomal degradation has
been shown in primary cardiac myocytes. In this study, over-
expression of the lysosomal protease cathepsin L decreased the
amount of inactive pSer21/9 GSK-3, whereas knockdown enhanced
the level of pSer21/9 GSK-3 (Tang et al., 2009). Both the classical GSK-
3 activator Wm and the widely used inhibitor LiCl affect the level of
pSer21/9 GSK-3 directly via phosphorylation. This mechanism is
different from the UPR-mediated regulation, because the GSK-3
protein levels are not affected.
Fig. 3. GSK-3 immunoreactive granules occur in neurons that have an activated UPR. Double immunohistochemistry was performed on a subset of our cohort using GSK-3/pSer21/9
GSK-3 and pPERK antibodies. (A) Low-magniﬁcation area of the CA1 region of a sporadic PiD case (#2) stained with GSK-3 (brown) and pPERK (pink) is shown. Nuclei were
counterstained with hematoxylin (blue). (B and C) Spectral imaging was performed on higher magniﬁcation images (B1, C1) to unmix the different chromogens and GSK-3 (B2, C2)
and pPERK (B3, C3) are shown separately and as a merge with artiﬁcial colors (GSK-3, green; pPERK, red; B4, C4). (D and E) The same approach was used for pSer21/9 GSK-3 (brown)
and pPERK (pink) double immunohistochemical stainings (D1, E1). Spectral imaging was performed; pSer21/9 GSK-3 (D2, E2) and pPERK (D3, E3) are shown separately and as
a merge with artiﬁcial colors (pSer21/9 GSK-3, green; pPERK, red; D4, E4). Representative neurons that contain (pSer21/9) GSK-3 reactive granules and pPERK (B and D) are shown.
Neurons lacking pPERK also do not contain (pSer21/9) GSK-3 reactive granules (C and E). Arrows indicate pPERK reactive granules, arrowheads indicate (pSer21/9) GSK-3 reactive
granules. Scale bars, 50 and 25 mm.
D.A.T. Nijholt et al. / Neurobiology of Aging 34 (2013) 1759e17711766In tauopathies, the inactive, Ser21/9-phosphorylated form of
GSK-3 was found to accumulate in granules in hippocampal
neurons. GSK-3 immunoreactive granules were previously
observed in hippocampal neurons in AD brain (Hoozemans et al.,
2009; Leroy et al., 2002). The presence of Ab in the AD brain maycomplicate the analysis of the connection between GSK-3 and the
UPR, as Ab was shown to increase GSK-3 activity (Takashima et al.,
1998) and to sensitize cells for UPR activation (Chafekar et al., 2007;
Chafekar et al., 2008). In our cohort of non-AD tauopathies, Ab
pathology was only rarely observed (Nijholt et al., 2011c), allowing
Fig. 4. GSK-3 reactive granules occur in neurons that contain phosphorylated tau pathology. Double immunohistochemistry was performed on a subset of our cohort using AT8 (p-
tau) and GSK-3/pSer21/9 GSK-3 antibodies. (A) Shown is a low magniﬁcation area of the CA1 region of a sporadic PiD case (#2) stained with AT8 (brown) and GSK-3 (pink). Nuclei
were counterstained with hematoxylin (blue). Spectral imaging was performed on higher-magniﬁcation images (B1, C1) to unmix the different chromogens; AT8 (B2, C2) and GSK-3
(B3, C3) are shown separately and as a merge with artiﬁcial colors (AT8, green; GSK-3, red, B4, C4). The same approach was used for AT8 and pSer21/9 GSK-3 double immuno-
histochemical stainings (E1, D1). Spectral imaging was performed; AT8 (D2, E2) and pSer21/9 GSK-3 (D3, E3) are shown separately and as a merge with artiﬁcial colors (AT8, green;
pSer21/9 GSK-3, red, D4, E4). Representative neurons that contain (pSer21/9) GSK-3 reactive granules and p-tau pathology (B and D) are shown. Neurons without AT8 positivity also do
not contain (pSer21/9) GSK-3 reactive granules (C and E). Arrowheads indicate (pSer21/9) GSK-3 reactive granules. Scale bar, 50 mm.
D.A.T. Nijholt et al. / Neurobiology of Aging 34 (2013) 1759e1771 1767study of the connection between UPR activation and GSK-3 without
confounding effects of Ab. Double immunohistochemistry revealed
pSer21/9 GSK-3 immunoreactive granules to occur in neurons of the
tauopathy brain that had activated the UPR (Nijholt et al., 2011c).
We previously demonstrated that in the AD and FTLD-tau brain,UPR activation occurs in neurons that contain diffusely distributed
p-tau. Our observations in this study further strengthen the
connection between UPR activation, GSK-3, and tau phosphoryla-
tion. pPERK and other UPR markers are commonly observed in
granules with a distinct morphological proﬁle, referred to as
Fig. 5. GSK-3 co-localizes with the lysosomal marker LAMP1. (A) Differentiated SK-N-SH cells and (B) mouse primary neurons were incubated for 16 hours with (Tm) or without
(ctrl) 1 and 5 mg/mL tunicamycin, respectively, to activate the UPR. Immunoﬂuorescent analyses were performed using GSK3b antibody and LAMP1 antibody as lysosomal marker.
Nuclei were counterstained with DAPI. GSK-3 localization was assessed by confocal microsopy. One representative image is shown for each condition.
D.A.T. Nijholt et al. / Neurobiology of Aging 34 (2013) 1759e17711768granulovacuolar degeneration (Hoozemans et al., 2009; Nijholt
et al., 2011c). We observed no direct colocalization of pPERK and
pSer21/9 GSK-3 reactive granules. Instead, a large fraction of pSer21/9,
GSK-3 was found to colocalize with cathepsin D immunoreactive
lysosomal structures, suggesting that inactive GSK-3 is targeted to
the lysosomes. In both SK-N-SH cells as well as in mouse primary
neurons, GSK-3 co-localizes with LAMP1 positive structures. This is
corroborated by in vitro data that show that inhibition of lysosomal
degradation prevents the UPR-induced decrease in GSK-3 levels. In
this experiment, we were unable to obtain informative results for
the degradation of pSer21/9 GSK-3, because treatment with BAF
alone decreased the level of pSer21/9 GSK-3. Stimulation of lyso-
somal degradation by amino acid starvation does induce a selective
decrease in pSer21/9 GSK-3, therefore the effect of BAF is probably
indirect. BAF was shown to induce changes in the phosphorylationof insulin receptor signaling components, including PKB/Akt, which
targets GSK-3 Ser21/9 (Hettiarachchi et al., 2006). Thus, the decrease
in pSer21/9 GSK-3 levels that we observe might be caused by BAF
acting on upstream components of the insulin signaling pathway.
Starvation activates the autophagy/lysosomal route by inhibiting
mTOR, the major regulator of autophagy induction. There are
multiple signaling pathways that interconnect mTORC complexes,
the UPR and GSK-3, that are not yet fully understood (Appenzeller-
Herzog and Hall, 2012). However, we observe that starvation affects
the total levels of GSK-3 and not the phosphorylation status, indi-
cating that it is mediated via autophagy/lysosomal degradation and
does not involve signaling via kinases that target GSK-3 Ser21/9.
In our cell model, pTyr216/279 GSK is apparently not subject to
UPR induced degradation. In addition, in post-mortem tissue, the
localization of this phosphorylated isoform is not changed in
Fig. 6. pSer21/9 GSK-3 granules co-localize with the lysosomal marker cathepsin D. Double immunohistochemistry was performed on a subset of our cohort. (A) High-magniﬁcation
image of the hippocampal CA1 region of a sporadic PiD case (#2) stained with pSer21/9 GSK-3 (brown) and cathepsin D (pink). Nuclei were counterstained with hematoxylin (blue).
(B) Spectral imaging was performed to unmix the different chromogens and to assign artiﬁcial colors (pSer21/9 GSK-3: green, cathepsin-D: red). (C) Colocalization between pSer21/9
GSK-3 and cathepsin D is shown in blue. Scale bar, 10 mm.
D.A.T. Nijholt et al. / Neurobiology of Aging 34 (2013) 1759e1771 1769tauopathies compared to control cases. We cannot exclude also that
some GSK-3 that is not phosphorylated at pSer21/9 is degraded.
However, the strongest UPR-induced decrease is in the fraction that
is phosphorylated at pSer21/9, suggesting that this phosphorylated
isoform is speciﬁcally targeted for degradation. UPR activation leads
to increased autophagy (Yorimitsu et al., 2006), which would be
a possible pathway to directmaterial for lysosomal degradation.We
previously reported that, during UPR activation, the autophagy/
lysosomal pathway is the preferred pathway for degradation
(Nijholt et al., 2011a). Induction of autophagy by starvation also
leads to a reduction in total and pSer21/9 GSK-3, indicating that GSK-
3 is a substrate macro autophagy. Alternatively, lysosomal targeting
of pSer21/9 GSK-3 may be achieved by fusion of a granule with
a lysosome, or pSer21/9 GSK-3 may be actively recruited to the
lysosomes via a mechanism like chaperone-mediated autophagy.
Autophagy is a dynamic process of which the activity is difﬁcult to
assess in situ (Klionsky et al., 2012). In our previous work, we
observed high levels of LC3 in neurons that had activated the UPR in
AD hippocampus, which is indicative of disturbed autophagic ﬂux
(Nijholt et al., 2011a). This may be caused by impaired lysosomal
function, which is a well-established feature of AD (Boland et al.,Fig. 7. UPR induces lysosomal degradation of GSK-3 in vitro. Levels of GSK-3 and pSer21/9 a
ELISA colorimetric assay and corrected for cell number using Janus Green staining. Value
a representative experiment; all measurements were performed in triplicate, and each exp
increasing concentrations of Tm for 16 hours in the presence or absence of BAF to study the e
(B) To investigate whether the GSK-3 phosphoforms are speciﬁc substrates for autophagy/l2008; Lee et al., 2010; Lee et al., 2011; Nijholt et al., 2011b; Nixon
et al., 2005). The accumulation of pSer21/9 GSK-3 may reﬂect the
recruitment of pSer21/9 GSK-3 into lysosomal compartments that are
not efﬁciently cleared because of an underlying defect in lysosomal
degradation. Our activity data indicate that the inhibitory phos-
phorylation of GSK-3 at Ser21/9, at least to some extent, functions as
a dominant negative. This would imply that also in the absence of
actual degradation, the sequestration of pSer21/9 GSK-3 into the
lysosomal compartment is expected to increase GSK-3 activity and
promote tau phosphorylation. Interestingly, in a recent report,
conditional and neuron-speciﬁc knockoutmice forAtg7, a key player
in autophagy, displayed inclusions of phosphorylated tau and GSK-
3. This apparently is a very selective effect, as other proteins asso-
ciated with neurodegenerative disorders like a-synuclein and APP/
Ab, or other tau kinases like CDK5 or GSK-3 substrates like b-catenin
do not accumulate in these autophagy-deﬁcient neurons (Inoue
et al., 2012). This supports an important role of the autophagy/
lysosomal system in the selective regulation of the activity of GSK-3
and the resulting phosphorylation of its substrate tau.
In summary, we have presented a novel mechanism by which
the UPR increases activity of the major tau kinase GSK-3. When UPRnd pTyr216/279 GSK-3 were determined in differentiated SK-N-SH cells using the InCell
s in untreated cells are set to 100%. Bars represent the mean  SEM of n ¼ 3 from
eriment was performed at least twice; *p < .05, **p < .01. (A) Cells were treated with
ffect of inhibition of lysosomal degradation on the Tm induced decrease in GSK-3 levels.
ysosomal degradation, cells were starved for 2 hours to induce autophagy.
D.A.T. Nijholt et al. / Neurobiology of Aging 34 (2013) 1759e17711770activation persists, a prolonged increase in GSK-3 activity may
disturb the balance between the activity of tau kinases and phos-
phatases in a way that favors increased tau phosphorylation and
aggregate formation.
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